Abstract: There is a present unmet need for non-invasive therapeutic methods for administration to brain cancer subjects that would provide a robust attack against their primary or metastatic brain cancer. The present disclosure describes such methods to therapeutically induce regression and/or elimination of primary and metastatic brain cancers through Transcranial Electromagnetic Treatment (TEMT). The methods involve 1) enhancement of brain meningeal lymph flow to increase immune trafficking between the brain cancer and cervical lymph nodes, 2) rebalancing of immune or non-immune signaling within the brain, particularly from the brain tumor to the lymphatic system, and/or 3) direct attack on cells within and around the brain tumor itself. Thus, the above described TEMT methods could induce and boost a specific immune or non-immune response to a given brain tumor, as well as directly attack the brain tumor, to provide an effective therapeutic intervention against both primary and metastatic brain cancers.

Abstract: The subject invention concerns materials and methods for treating a person or animal having cognitive impairment. In one embodiment, the method comprises administering an effective amount of one or more inflammatory mediator(s), for example, fms-related tyrosine kinase 3 (Flt3) ligand, interleukin-6 (IL-6), macrophage migration inhibitory factor (MIF), interleukin-1 (IL-1), interleukin-3 (IL-3), erythropoietin (EPO), vascular endothelial growth factor A (VEGF-A), hypoxia-inducible transcription factor (HIF-1alpha), insulin like growth factor-1 (IGF-1), tumor necrosis factor (TNF), granulocyte colony-stimulating factor (G-CSF), granulocyte/macrophage colony-stimulating factor (GM-CSF), macrophage colony-stimulating factor (M-CSF), Stem Cell Factor (SCF), Darbepoetin (ARANESP), and metalloproteinases, to an animal or person in need of treatment.

Abstract: In one example in accordance with the present disclosure, an emitter system is described. The emitter system includes an array of emitters. Each emitter emits waves towards a target surface. The emitter system also includes a control system. The control system includes a sensing system to determine whether emitters in the array are properly positioned relative to the target surface. A controller of the control system adjusts emitter sets of the array of emitters based on an output of the sensing system.

Abstract: In one example in accordance with the present disclosure a method is described. According to the method, an emitter of a transcranial electromagnetic treatment (TEMT) system is positioned at a location relative to a head of a patient such that the emitter emits an electromagnetic frequency signal toward the head of the patient. The emitter is activated to apply TEMT to the patient to treat amyloid oligomers. In some examples, the TEMT has a frequency between 1 MHz and 430 THz.

Abstract: In one example in accordance with the present disclosure a method of normalizing cytokine levels in a blood stream of a subject is described. According to the method, an array of electromagnetic emitters is positioned proximal to the subject. An electromagnetic wave generator generates electromagnetic fields having a predetermined frequency. Cytokine levels are normalized in the blood stream of the subject by applying the electromagnetic fields to the subject through the electromagnetic emitters.

Abstract: In one example in accordance with the present disclosure, an antenna system is described. The antenna system includes an array of antennas. Each antenna emits electromagnetic waves and is presented with a load that is different from other antennas in the array. The antenna system also includes a control system. The control system includes a single transmitter to sequentially drive antenna sets, a switching device to select, for each activation period in an activation sequence, an antenna set to be driven, and a controller. The controller determines an actual power output of each antenna and generates an adjusted control signal for the single transmitter such that the output of each antenna is controlled to match a target power for that antenna, regardless of a load for the antenna.

Abstract: The present disclosure describes methods and devices for increasing human life span (longevity) via electromagnetic treatment. An array of electromagnetic emitters are positioned proximal to a subject. An electromagnetic wave generator generates electromagnetic fields having a predetermined set of parameters. Life span is increased by applying the electromagnetic waves to the subject through the electromagnetic emitters.

Abstract: There is a present unmet need for non-invasive therapeutic methods for administration to brain cancer subjects that would provide a robust attack against their primary or metastatic brain cancer. The present disclosure describes such methods to therapeutically induce regression and/or elimination of primary and metastatic brain cancers through Transcranial Electromagnetic Treatment (TEMT). The methods involve 1) enhancement of brain meningeal lymph flow to increase immune trafficking between the brain cancer and cervical lymph nodes, 2) rebalancing of immune or non-immune signaling within the brain, particularly from the brain tumor to the lymphatic system, and/or 3) direct attack on cells within and around the brain tumor itself. Thus, the above described TEMT methods could induce and boost a specific immune or non-immune response to a given brain tumor, as well as directly attack the brain tumor, to provide an effective therapeutic intervention against both primary and metastatic brain cancers.

Abstract: The present disclosure describes a method of regulating (re-balancing) the brain's immune system to decrease occurrence and/or severity of age-related diseases and increase life span. According to the method, an array of electromagnetic emitters are positioned proximal to the subject. An electromagnetic wave generator generates electromagnetic waves at a predetermined set of parameters. In an example of the emitters positioned proximal to the subject's head, the brain's immune function is normalized/rebalanced in an area under the electromagnetic emitters by applying the electromagnetic waves to the subject through the electromagnetic emitters. With either head or body placement of emitters, a rebalancing of the brain's cytokines/immune mediators occurs, which should result in less occurrence or severity of age-related diseases and, thus, increase human life span.

Abstract: The subject invention concerns materials and methods for treating a person or animal having cognitive impairment. In one embodiment, the method comprises administering an effective amount of one or more inflammatory mediator(s), for example, fins-related tyrosine kinase 3 (Fltt3) ligand, interleukin-6 (IL-6), macrophage migration inhibitory factor (MIF), interleukin-1 (IL-1), interleukin-3 (IL-3), erythropoietin (EPO), vascular endothelial growth factor A (VEGF-A), hypoxia-inducible transcription factor (HIF-1 alpha), insulin like growth factor-1 (IGF-1), tumor necrosis factor (TNF), granulocyte colony-stimulating factor (G-CSF), granulocyte/macrophage colony-stimulating factor (GM-CSF), macrophage colony-stimulating factor (M-CSF), Stem Cell Factor (SCF), Darbepoetin (ARANESP), and metalloproteinases, to an animal or person in need of treatment.

Abstract: In one example in accordance with the present disclosure a method is described. According to the method, an emitter of a transcranial electromagnetic treatment (TEMT) system is positioned at a location relative to a head of a patient such that the emitter emits an electromagnetic frequency signal toward the head of the patient. The emitter is activated to apply TEMT to the patient to treat amyloid oligomers. In some examples, the TEMT has a frequency between 1 MHz and 430 THz.

Abstract: Disclosed are devices, methods, and systems for helping to prevent (or preventing) or treat brain and/or body disorders. Embodiments of the invention have utility for enhancing cognitive function during aging. The invention utilizes electromagnetic stimulation (EMS) that can provide a range of EMS parameters and modalities. The EMS may be utilized in conjunction with physiologic sensors that can provide feedback for possible EMS modifications.

Abstract: In one example in accordance with the present disclosure a method of normalizing cytokine levels in a blood stream of a subject is described. According to the method, an array of electromagnetic emitters is positioned proximal to the subject. An electromagnetic wave generator generates electromagnetic fields having a predetermined frequency. Cytokine levels are normalized in the blood stream of the subject by applying the electromagnetic fields to the subject through the electromagnetic emitters.

Abstract: In one example in accordance with the present disclosure, an emitter system is described. The emitter system includes an array of emitters. Each emitter emits waves towards a target surface. The emitter system also includes a control system. The control system includes a sensing system to determine whether emitters in the array are properly positioned relative to the target surface. A controller of the control system adjusts emitter sets of the array of emitters based on an output of the sensing system.

Abstract: In one example in accordance with the present disclosure, an antenna system is described. The antenna system includes an array of antennas. Each antenna emits electromagnetic waves and is presented with a load that is different from other antennas in the array. The antenna system also includes a control system. The control system includes a single transmitter to sequentially drive antenna sets, a switching device to select, for each activation period in an activation sequence, an antenna set to be driven, and a controller. The controller determines an actual power output of each antenna and generates an adjusted control signal for the single transmitter such that the output of each antenna is controlled to match a target power for that antenna, regardless of a load for the antenna.

Abstract: A method of treating and preventing a neurological disorder, such as Alzheimer's disease, in a subject in need thereof by positioning an electromagnetic field emitting source proximal to the subject and exposing the subject to an electromagnetic field having a predetermined frequency (preferably ?300-3,000 MHz) for a predetermined absorption period (preferably greater than ?3 days). Each individual treatment (comprising exposure to the predetermined frequency for the predetermined absorption period) is continued at a predetermined schedule for a predetermined treatment period. The EMF can have a specific absorption rate up to about 8 W/kg. The methodology enhances cognition in the subject and/or treats/prevents the underlying neurological disorder or a symptom thereof.

Abstract: The subject invention concerns materials and methods for treating a person or animal having cognitive impairment. In one embodiment, the method comprises administering an effective amount of one or more inflammatory mediator(s), for example, fms-related tyrosine kinase 3 (Flt3) ligand, interleukin-6 (IL-6), macrophage migration inhibitory factor (MIF), interleukin-1 (IL-1), interleukin-3 (IL-3), erythropoietin (EPO), vascular endothelial growth factor A (VEGF-A), hypoxia-inducible transcription factor (HIF-1alpha), insulin like growth factor-1 (IGF-1), tumor necrosis factor (TNF), granulocyte colony-stimulating factor (G-CSF), granulocyte/macrophage colony-stimulating factor (GM-CSF), macrophage colony-stimulating factor (M-CSF), Stem Cell Factor (SCF), Darbepoetin (ARANESP), and metalloproteinases, to an animal or person in need of treatment.

Abstract: The subject invention concerns materials and methods for treating a person or animal having cognitive impairment. In one embodiment, the method comprises administering an effective amount of one or more inflammatory mediator(s), for example, fms-related tyrosine kinase 3 (Flt3) ligand, interleukin-6 (IL-6), macrophage migration inhibitory factor (MIF), interleukin-1 (IL-1), interleukin-3 (IL-3), erythropoietin (EPO), vascular endothelial growth factor A (VEGF-A), hypoxia-inducible transcription factor (HIF-1alpha), insulin like growth factor-1 (IGF-1), tumor necrosis factor (TNF), granulocyte colony-stimulating factor (G-CSF), granulocyte/macrophage colony-stimulating factor (GM-CSF), macrophage colony-stimulating factor (M-CSF), Stem Cell Factor (SCF), Darbepoetin (ARANESP), and metalloproteinases, to an animal or person in need of treatment.

Abstract: A method of treating and preventing a neurological disorder, such as Alzheimer's disease, in a subject in need thereof by positioning an electromagnetic field emitting source proximal to the subject and exposing the subject to an electromagnetic field having a predetermined frequency (preferably ?300-3,000 MHz) for a predetermined absorption period (preferably greater than ?3 days). Each individual treatment (comprising exposure to the predetermined frequency for the predetermined absorption period) is continued at a predetermined schedule for a predetermined treatment period. The EMF can have a specific absorption rate up to about 8 W/kg. The methodology enhances cognition in the subject and/or treats/prevents the underlying neurological disorder or a symptom thereof.

Abstract: The invention includes a method of treating and preventing a neurological disorder, such as Alzheimer's Disease, in a subject in need thereof by positioning an electromagnetic field emitting source proximal to the subject and exposing the subject to an electromagnetic field having a predetermined frequency for a predetermined absorption period. Preferably, each individual treatment (comprising exposure to the predetermined frequency for the predetermined absorption period) is continued at a predetermined schedule (preferably daily) for a predetermined treatment period. The predetermined frequency, according to a preferred embodiment, is about 918 MHz with a specific absorption rate (SAR) of about 0.25 W/kg+/?2 dB. The predetermined absorption period of this preferred embodiment is about one hour. The treatment period is long-term, being greater than about 6 months and preferably between about 7 and 9 months.